ONL Therapeutics key facts
- Operator of a biopharmaceutical company intended to protect and improve patients' vision with various retinal diseases and conditions.
- It has raised $132.5M across 10 recorded rounds; the latest was Later Stage VC ($60.0M) in Sep 2024.
- Notable investors include National Institutes of Health, Johnson & Johnson JJDC, Innovation Partnerships, Novartis Venture Fund, University of Michigan Endowment — 26 tracked in total.
- ONL Therapeutics has filed 10 Form Ds with the SEC since 2014, most recently Sep 2024 ($60.0M sold to 35 investors).
- Status: Privately Held (backing).
Who backs ONL Therapeutics
26+Membership and data by Private Market View
- ·The complete investor list: 26 names
- ·Watch ONL Therapeutics: the Monday email on marks, rounds and moves
ONL Therapeutics funding rounds
10 roundsHow much has ONL Therapeutics raised?
ONL Therapeutics has raised $133 million across 10 recorded rounds since 2014. The largest was a $10 million early-stage round in Feb 2024; the most recent was a $60 million later-stage round in Sep 2024.
ONL Therapeutics has filed 10 Form Ds with the SEC since 2014, most recently in Sep 2024 ($60 million sold to 35 investors).
ONL Therapeutics investors
26 investors are on record for ONL Therapeutics, including National Institutes of Health, Johnson & Johnson JJDC, Innovation Partnerships and Novartis Venture Fund. The later-stage round in Sep 2024 drew 35 investors.
About ONL Therapeutics
Operator of a biopharmaceutical company intended to protect and improve patients' vision with various retinal diseases and conditions. The company develops therapeutics treatments for serious, vision-threatening retinal diseases and conditions with small-molecule peptides for the protection of photoreceptors in retinal detachment, enabling patients to have successful surgeries and improved outcomes.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2011
- Employees
- 29
- Website
- onltherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ONL Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.